Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Research

Efficacy of treatment patterns based on concurrent chemoradiotherapy in patients with stage IIB cervical squamous cell carcinoma

Authors: Xin-Bin Pan, Yan Lu, You-Sheng Wei, De-Sheng Yao

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Purpose

To assess survival of treatment patterns based on concurrent chemoradiotherapy (CCRT) in patients with stage IIB cervical squamous cell carcinoma (CSCC).

Materials and methods

Patients with stage IIB CSCC receiving CCRT were investigated from June 2012 to June 2019 in Guangxi Medical University Cancer Hospital. Baseline characteristics and treatment patterns were described. Survival between treatment patterns were compared using Kaplan-Meier methods.

Results

A total of 232 patients were included: 39.7% of patients received CCRT alone, 6.5% of patients received neoadjuvant chemotherapy (NACT) + CCRT, 45.6% of patients received CCRT + adjuvant chemotherapy (AC), and 8.2% of patients received NACT + CCRT + AC. CCRT + AC showed similar overall survival (OS; hazard ratio [HR] = 0.95, 95% confidence interval [CI]: 0.41–2.17; P = 0.894) and locoregional-free survival (LRFS; HR = 2.39, 95% CI: 0.45–12.63; P = 0.303) compared with CCRT. However, CCRT + AC had a worse distant metastasis-free survival (DMFS; HR = 5.39, 95% CI: 1.14–25.57; P = 0.034). After propensity score matching, CCRT + AC had comparable OS (HR = 0.89, 95% CI: 0.29–2.70; P = 0.833), LRFS (HR = 3.26, 95% CI: 0.30-35.38; P = 0.331), and DMFS (HR = 4.80, 95% CI: 0.55–42.26; P = 0.157) compared to CCRT.

Conclusion

AC did not improve survival in patients with stage IIB CSCC receiving CCRT.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.CrossRef
2.
Zhang M, Zhong Y, Zhao Z, Huang Z, Zhang X, Li C, et al. Cervical Cancer Screening Rates among Chinese Women - China, 2015. China CDC Wkly. 2020;2(26):481–6.PubMedPubMedCentralCrossRef
3.
Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–53.PubMedCrossRef
4.
Chemoradiotherapy for Cervical Cancer Meta-Analysis C. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncology: Official J Am Soc Clin Oncol. 2008;26(35):5802–12.CrossRef
5.
Cibula D, Potter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie-Meder C, et al. The european Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the management of patients with cervical Cancer. Virchows Arch. 2018;472(6):919–36.PubMedCrossRef
6.
Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl4):iv72–iv83.PubMedCrossRef
7.
Zhong L, Li K, Song L, Yin R. The effect of consolidation chemotherapy after concurrent chemoradiation on the prognosis of locally advanced cervical cancer: a systematic review and meta-analysis. J Obstet Gynaecology: J Inst Obstet Gynecol. 2022;42(5):830–7.CrossRef
8.
Liu H, Ma X, Sun C, Wu M, Xu Z, Zhou S, et al. Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:997030.PubMedPubMedCentralCrossRef
9.
Ma X, Fang J, Zhang L, Huang Y, Shen H, Ma X, et al. Efficacy and safety of adjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis. Crit Rev Oncol/Hematol. 2023;184:103953.PubMedCrossRef
10.
Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database Syst Rev. 2014;2014(12):CD010401.PubMedPubMedCentral
11.
Qiao Y, Li H, Peng B. Neoadjuvant and adjuvant treatments compared to concurrent chemoradiotherapy for patients with locally Advanced Cervical Cancer: a bayesian network Meta-analysis. Front Oncol. 2022;12:745522.PubMedPubMedCentralCrossRef
12.
Mabuchi S, Isohashi F, Okazawa M, Kitada F, Maruoka S, Ogawa K, et al. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients. J Gynecologic Oncol. 2017;28(1):e15.CrossRef
13.
Kou L, Zhang T, Yang X, Peng S, Wang Y, Yuan M, et al. Role of adjuvant chemotherapy after concurrent chemoradiotherapy in patients with locally advanced cervical cancer. Future Oncol. 2022;18(16):1917–5.PubMedCrossRef
14.
Mileshkin LR, Moore KN, Barnes EH, Gebski V, Narayan K, King MT, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(5):468–82.PubMedCrossRef
15.
Tangjitgamol S, Tharavichitkul E, Tovanabutra C, Rongsriyam K, Asakij T, Paengchit K, et al. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial. J Gynecologic Oncol. 2019;30(4):e82.CrossRef
16.
Ali N, Valimohammad AT, Abbasi AN, Mansha MA, Hafiz A, Qureshi BM. Chemoradiation and the role of Adjuvant Chemotherapy in Lymph nodal-metastatic cervical Cancer. J Global Oncol. 2018;4:1–4.
17.
de Azevedo C, Thuler LCS, de Mello MJG, de Oliveira Lima JT, da Fonte ALF, Fontao DFS, et al. Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer. Gynecol Oncol. 2017;146(3):560–5.PubMedCrossRef
18.
da Costa SCS, Bonadio RC, Gabrielli FCG, Aranha AS, Dias Genta MLN, Miranda VC, et al. Neoadjuvant Chemotherapy with Cisplatin and Gemcitabine followed by Chemoradiation Versus Chemoradiation for locally Advanced Cervical Cancer: a randomized phase II trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37(33):3124–31.CrossRef
19.
McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs MA, Symonds RP, Warwick V, et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer. 2013;108(12):2464–9.PubMedPubMedCentralCrossRef
20.
Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019;145(1):129–35.PubMedCrossRef
21.
Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, et al. Neoadjuvant Chemotherapy followed by radical surgery Versus Concomitant Chemotherapy and Radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical Cancer: a Randomized Controlled Trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2018;36(16):1548–55.CrossRef
22.
Gadducci A, Cosio S. Neoadjuvant chemotherapy in locally Advanced Cervical Cancer: review of the literature and perspectives of Clinical Research. Anticancer Res. 2020;40(9):4819–28.PubMedCrossRef
23.
Chidambaram S, Owen R, Sgromo B, Chmura M, Kisiel A, Evans R et al. Delayed Surgical Intervention After Chemoradiotherapy in Esophageal Cancer: (DICE) Study. Annals of surgery. 2023.
24.
Glynne-Jones R, Hoskin P. Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm? J Clin Oncology: Official J Am Soc Clin Oncol. 2007;25(33):5281–6.CrossRef
25.
Hu K, Wang W, Liu X, Meng Q, Zhang F. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy. Radiat Oncol. 2018;13(1):249.PubMedPubMedCentralCrossRef
26.
Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncology: Official J Am Soc Clin Oncol. 2011;29(13):1678–85.CrossRef
27.
Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv262.PubMedCrossRef
28.
29.
Yuan Y, You J, Li X, Wang W. Adjuvant chemotherapy after radiotherapy or concurrent chemoradiotherapy for pelvic lymph node-positive patients with locally advanced cervical cancer: a propensity score matching analysis. Int J Gynecol cancer: Official J Int Gynecol Cancer Soc. 2022;32(1):21–7.CrossRef
Metadata
Title
Efficacy of treatment patterns based on concurrent chemoradiotherapy in patients with stage IIB cervical squamous cell carcinoma
Authors
Xin-Bin Pan
Yan Lu
You-Sheng Wei
De-Sheng Yao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11372-6

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Subjective and objective financial toxicity among colorectal cancer patients: a systematic review

Research

The selective sponging of miRNAs by OIP5-AS1 regulates metabolic reprogramming of pyruvate in adenoma-carcinoma transition of human colorectal cancer

Research

Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials

Research

Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany

Research

Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy

Research

Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits